Arbutus Biopharma (ABUS) Reports FY18 Loss of $1.21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ABUS Hot Sheet
Join SI Premium – FREE
Arbutus Biopharma (NASDAQ: ABUS) reported FY18 EPS of ($1.21), versus ($1.56) reported last year. Revenue for the year came in at $5.9 million, versus $10.7 million reported last year.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- SanDisk stock tumbles as Kioxia warns on NAND price surge
- enVVeno Medical (NVNO) Misses Q3 EPS by 302c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
